Phase Ib trial of CALAA 01 to investigate an alternative dosing regimen in patients with solid tumours that are refractory to standard-of-care therapies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2012
At a glance
- Drugs CALAA 01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Calando Pharmaceuticals
- 30 Aug 2012 Status changed from planning to active, no longer recruiting, according to an Arrowhead Research Corporation media release.
- 15 Aug 2012 Additional patients were dosed, according to an Arrowhead Research Corporation media release.
- 16 Aug 2011 New trial record